Vanessa Shurtleff1, John J Radosevich1, Asad E Patanwala2. 1. Department of Pharmacy Services, St Joseph's Hospital and Medical Center-Dignity Health, Phoenix, AZ, USA. 2. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Abstract
BACKGROUND: At this time, there are no studies evaluating the risk of delirium or coma with the use of ketamine in mechanically ventilated adult patients, compared to conventional therapies such as propofol or dexmedetomidine. OBJECTIVE: The objective of this study was to evaluate the number of days alive without delirium or coma in mechanically ventilated patients in the intensive care unit receiving analgosedation infusions with ketamine versus without ketamine. METHODS: This was a retrospective cohort study conducted at an academic medical center in the United States. Consecutive mechanically ventilated adult patients between November 2015 and April 2017 were evaluated. Patients were divided into 2 groups based on the sedative regimen used: ketamine based or nonketamine based. The primary outcome was the number of days alive without delirium or coma. The secondary outcomes were incidence of delirium, incidence of coma, and ventilator-free days at day 28. RESULTS: The study cohort consisted of 79 patients, of which 39 received ketamine- and 40 received nonketamine-based sedation. The number of days alive without delirium or coma was 6 days (interquartile range [IQR]: 2-9 days) with ketamine and 4 days (IQR: 3-7 days) with nonketamine (P = .351). Delirium occurred in 29 (74%) of 39 patients with ketamine and 34 (85%) of 40 patients with nonketamine (P = .274). Coma occurred in 16 (41%) of 39 patients with ketamine and 6 (15%) of 40 patients with nonketamine (P = .013). The median ventilator-free days were 13 days (IQR: 0-23 days) with ketamine and 21 days (0-25 days) with nonketamine (P = .229). CONCLUSIONS: Sustained ketamine-based sedation in mechanically ventilated patients may be associated with a higher rate of observed coma but similar delirium- and coma-free days compared nonketamine-based regimens.
BACKGROUND: At this time, there are no studies evaluating the risk of delirium or coma with the use of ketamine in mechanically ventilated adult patients, compared to conventional therapies such as propofol or dexmedetomidine. OBJECTIVE: The objective of this study was to evaluate the number of days alive without delirium or coma in mechanically ventilated patients in the intensive care unit receiving analgosedation infusions with ketamine versus without ketamine. METHODS: This was a retrospective cohort study conducted at an academic medical center in the United States. Consecutive mechanically ventilated adult patients between November 2015 and April 2017 were evaluated. Patients were divided into 2 groups based on the sedative regimen used: ketamine based or nonketamine based. The primary outcome was the number of days alive without delirium or coma. The secondary outcomes were incidence of delirium, incidence of coma, and ventilator-free days at day 28. RESULTS: The study cohort consisted of 79 patients, of which 39 received ketamine- and 40 received nonketamine-based sedation. The number of days alive without delirium or coma was 6 days (interquartile range [IQR]: 2-9 days) with ketamine and 4 days (IQR: 3-7 days) with nonketamine (P = .351). Delirium occurred in 29 (74%) of 39 patients with ketamine and 34 (85%) of 40 patients with nonketamine (P = .274). Coma occurred in 16 (41%) of 39 patients with ketamine and 6 (15%) of 40 patients with nonketamine (P = .013). The median ventilator-free days were 13 days (IQR: 0-23 days) with ketamine and 21 days (0-25 days) with nonketamine (P = .229). CONCLUSIONS: Sustained ketamine-based sedation in mechanically ventilated patients may be associated with a higher rate of observed coma but similar delirium- and coma-free days compared nonketamine-based regimens.
Authors: Christine M Groth; Christopher A Droege; Kathryn A Connor; Kimberly Kaukeinen; Nicole M Acquisto; Sai Ho J Chui; Michaelia D Cucci; Deepali Dixit; Alexander H Flannery; Kyle A Gustafson; Nina E Glass; Helen Horng; Mojdeh S Heavner; Justin Kinney; Rachel M Kruer; William J Peppard; Preeyaporn Sarangarm; Andrea Sikora; Velliyur Viswesh; Brian L Erstad Journal: Crit Care Explor Date: 2022-02-10
Authors: Habib Mr Karim; Irena Šarc; Camilla Calandra; Savino Spadaro; Bushra Mina; Laura D Ciobanu; Gil Gonçalves; Vania Caldeira; Bruno Cabrita; Andreas Perren; Giuseppe Fiorentino; Tughan Utku; Edoardo Piervincenzi; Mohamad El-Khatib; Nilgün Alpay; Rodolfo Ferrari; Mohamed Ea Abdelrahim; Haitham Saeed; Yasmin M Madney; Hadeer S Harb; Nicola Vargas; Hilmi Demirkiran; Pradipta Bhakta; Peter Papadakos; Manuel Á Gómez-Ríos; Alfredo Abad; Jaber S Alqahtani; Vijay Hadda; Subrata K Singha; Antonio M Esquinas Journal: Indian J Crit Care Med Date: 2022-08
Authors: Katalina Chan; Lisa D Burry; Christopher Tse; Hannah Wunsch; Charmaine De Castro; David R Williamson Journal: Ann Pharmacother Date: 2022-01-26 Impact factor: 3.463
Authors: Mohammed Bawazeer; Marwa Amer; Khalid Maghrabi; Kamel Alshaikh; Rashid Amin; Muhammad Rizwan; Mohammad Shaban; Edward De Vol; Mohammed Hijazi Journal: Trials Date: 2020-03-20 Impact factor: 2.279